Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BSA-based vs concentration-based cisplatin dosing for HIPEC in advanced ovarian cancer
2021-006809-29Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cisplatin in High-Grade Serous Ovarian Cancer (HGSOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Intratumoral platinum concentration at end of HIPEC. Started May 2022; status: active.
02
Drugs
cisplatin
03
Conditions
High-Grade Serous Ovarian Cancer (HGSOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2021-006809-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006809-29.